Physician profile
Peter Kazmier
NPI 1811964273
$1,101.87
in general payments reported to CMS, 2019-2025
14 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Orthopaedic Trauma provider received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.02 · 2020: $20.33 · 2021: $270 · 2022: $116 · 2023: $286 · 2024: $153 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $297.31 | 2021-2023 | Na |
| Smith+Nephew, INC. | $214.60 | 2021-2025 | Grafix Pl, Grafix |
| Horizon Therapeutics Plc | $194.00 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $88.67 | 2025 | |
| Coastal Medical Technologies LLC | $62.18 | 2024-2025 | |
| Integra Lifesciences Corporation | $51.12 | 2022-2023 | Tenoglide |
| Polynovo North America LLC | $37.16 | 2024 | Novosorb Btm |
| Mvp Orthopedics INC | $33.06 | 2022 | |
| My01 INC. | $26.75 | 2025 | My01 Continuous Compartmental Pressure Monitor |
| Si-Bone, INC. | $22.17 | 2024 | |
| Bioventus LLC | $20.33 | 2020 | |
| Kerecis Limited | $20.23 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Solventum Corporation | $17.76 | 2025 | Prevena |
| Wright Medical Technology, INC. | $16.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kazmier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.